Blood test takes step toward predicting Alzheimer's

Tony Wyss-Coray

Tony Wyss-Coray

One of the most distressing aspects of Alzheimer's disease is the difficulty in determining whether mild memory problems are the beginning of an inevitable mental decline. Researchers at the School of Medicine have developed a blood test that is a step toward giving people an answer two to six years before the onset of the disease.

The test identifies changes in a handful of proteins in blood plasma that cells use to convey messages to one another. The research team discovered a connection between shifts in the cells' dialog and the changes in the brain accompanying Alzheimer's. They found that the blood test could indicate who had Alzheimer's with 90 percent agreement with clinical diagnoses.

They also found the test could predict the onset of Alzheimer's two to six years before symptoms appeared, although the predictions did not match as closely to later clinical diagnoses.

'Just as a psychiatrist can conclude a lot of things by listening to the words of a patient, so by 'listening' to different proteins we are measuring whether something is going wrong in the cells,' said Tony Wyss-Coray, PhD, associate professor of neurology and neurological sciences and senior author of the study.

'It's not that the cells are using new words when something goes wrong,' said Wyss-Coray. 'It's just that some words are much stronger and some are much weaker; the chatter has a different tone.'

The study appeared in the Oct. 14 advance online edition of Nature Medicine.

'I really think it has enormous potential,' said Lennart Mucke, MD, director and senior investigator of the Gladstone Institute of Neurological Disease at the University of California-San Francisco, who did not participate in the study. 'Most researchers in this field agree that there is an urgent need for better lab tests for Alzheimer's disease, and this study has addressed this need admirably.'

Listening to cells' messages could also lead to similar discoveries about other disorders by focusing on what cells use to talk to each other, said Wyss-Coray, who is part of the Geriatric Research, Education and Clinical Center at the Veterans Affairs Palo Alto Health Care System.

Currently, the clinical diagnosis for Alzheimer's is one of exclusion - by testing for other causes of memory loss and cognitive declines, such as stroke, tumors and alcoholism. If those conditions are eliminated as causes of memory loss, what remains is Alzheimer's, which is the most common cause of dementia. Even the clinical diagnosis is imperfect, and the only definitive diagnosis is by brain autopsy after a person has died.

According to the Alzheimer's Association, more than 5 million Americans are afflicted with the disease, which robs patients of memory, thinking and the ability to communicate.

The blood-test concept began when Wyss-Coray and Sandip Ray, one of the two first authors of the paper, collaborated to measure levels of 120 different proteins used by cells to communicate to see if any of them could be indicators for Alzheimer's.

At the time the work was done, Ray was an employee of Satoris Inc., a company co-founded by Ray, Wyss-Coray and Yuen So, MD, PhD, professor of neurology and neurological sciences. Wyss-Coray is a consultant for Satoris.

Ray used blood samples from five people diagnosed with Alzheimer's, and compared those to samples from five who didn't have the disease. He found a number of proteins used for communication that demonstrated striking differences between the two groups.

Markus Britschgi, PhD, a postdoctoral scholar in Wyss-Coray's lab, was intrigued with the idea that proteins used by cells to communicate could be measured in the blood to see what is going on in the body, including the brain.

'This study made me realize that we should get away from this image of a brain isolated from the body,' said Britschgi, who is also a first author of the paper. 'The brain is part of the body and so it's connected in one huge network.'

Reaching out to clinics in the United States, as well as Sweden, Poland and Italy, Britschgi obtained a total of 259 archived blood samples from individuals who had symptoms ranging from nothing abnormal to mild cognitive impairment to advanced Alzheimer's. Starting with 120 communication proteins, the team developed an analysis procedure to recognize if there was a pattern seen in Alzheimer's that could be compared with that of people without the condition. They discovered that as few as 18 proteins were sufficient to identify an Alzheimer's-specific pattern.

Among blood samples from 92 individuals who ranged from no symptoms to full dementia, the protein analysis matched the clinical diagnosis 90 percent of the time.

They then asked if they could predict the development of Alzheimer's among 47 people with mild cognitive impairment who had been followed from two to six years. The test - done on blood samples taken several years earlier - flagged 91 percent of the patients who developed Alzheimer's by the end of the follow-up time, as diagnosed by conventional methods.

The results matched a negative clinical diagnosis less often, 72 percent of the time. But the researchers said it is often difficult to conclude someone definitely does not have Alzheimer's, as it is a progressive deterioration.

'Already we have people approaching us at meetings asking if they can give us a vial of their grandfather's blood for testing,' said Britschgi. Their findings show that it is possible to use factors in the blood to diagnose and even predict the disease, but, the authors emphasized, it must now be confirmed in other labs.

According to Satoris, the company will develop a commercial Alzheimer's blood test, initially for use in research laboratories and, if confirmed, later as a clinical diagnostic test after regulatory approval.

Britschgi and Wyss-Coray are interested in finding out why the cell communication pathways are altered in Alzheimer's. In their study, they determined that the 18 proteins that indicate Alzheimer's are also involved in the production of new blood cells, immune processes and apoptosis, the process of programmed cell death.

'Our hypothesis is that there is something wrong with the production of certain blood cells, which may be needed to clear that stuff that accumulates in the brain in Alzheimer's disease,' said Wyss-Coray. 'It is very exciting to think of immune cells and molecules interacting with the brain.'

The study's 25 authors include six other contributors from Stanford: Yoshiko Takeda-Uchimura, a research associate in Wyss-Coray's lab; Leah Friedman, PhD, senior research scholar in psychiatry and behavioral sciences; William Robinson, MD, PhD, assistant professor of medicine; Jared Tinklenberg, MD, professor of psychiatry and behavioral sciences; Jerome Yesavage, MD, professor of psychiatry and behavioral sciences, and Robert Tibshirani, PhD, professor of health research and policy and of statistics. Tibshirani is also a consultant for Satoris.

The study was supported by the John Douglas French Alzheimer's Foundation, the Alzheimer's Association, the National Institute of Aging and Satoris.


Stanford Medicine integrates research, medical education and health care at its three institutions - Stanford University School of Medicine, Stanford Health Care (formerly Stanford Hospital & Clinics), and Lucile Packard Children's Hospital Stanford. For more information, please visit the Office of Communication & Public Affairs site at http://mednews.stanford.edu.

Leading in Precision Health

Stanford Medicine is leading the biomedical revolution in precision health, defining and developing the next generation of care that is proactive, predictive and precise. 

A Legacy of Innovation

Stanford Medicine's unrivaled atmosphere of breakthrough thinking and interdisciplinary collaboration has fueled a long history of achievements.